Keyword: Giovanni Caforio
With BMS' Celgene deal recently closed, CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when Bristol unveiled it.
Bristol CEO Caforio figures the company's Celgene buy will fortify its position regardless of where the ongoing drug pricing debate goes.
Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.
Bristol-Myers Squibb plans to take on tens of billions in new debt to fund its Celgene buy, but execs have said they plan to quickly pay it down.
Bristol-Myers CEO Giovanni Caforio's 2018 pay package gained on revenue growth and Celgene negotiations—but took a hit from R&D results.
Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.
Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to buy Celgene. But it ended up striking a better deal instead.
Ever wish you could be a fly on the wall at a company in the middle of a merger? Thanks to the Securities and Exchange Commission, you can.